Lexogen, an ambitious new biotech company, is developing a set of complementary technologies that will present a breakthrough in the level of detail that RNA expression can be profiled.

Lexogen’s proprietary SQUARE technology presents a unique, hypothesis-free approach to reduce the complexity of the transcriptome and empowers Next Generation Sequencing technologies to sequence and quantify all splice variants in which genes are expressed. Lexogen's SQUARE technology will provide unprecedented insight in molecular pathways.

In addition, Lexogen is developing new technologies for the targeted analysis of defined transcripts of interest.